Group items tagged

This funding opportunity announcement (FOA) supports the development of PET radioligands that identify proteinopathies or pathological processes associated with the human biology of Alzheimer's disease related dementias (ADRDs). Activities supported under this FOA include, but are not limited to the in vitro screening of existing ligands against human ADRD brain tissue, medicinal chemistry support for development of new compounds and improvement of existing ligand specificity and selectivity, initial screening of ligands in appropriate animal models, and radioligand formulation and first-in-human testing. The Center without Walls should encompass research that will move promising ligands through in vitro and in vivo optimization to first-in-human studies. Applications must include an administrative core, a medicinal chemistry core, a clinical core, a scientific governance structure, and a minimum of two research projects with milestone plans that address workflows for screening of existing and newly derived ligands against human ADRD tissue and appropriate animal models. Synergy must be evident among Center research projects and cores, such that successful completion of the aims could not be accomplished without the Center structure.

Projects proposed for the BYI program should be truly innovative, high-risk, and show promise for contributing to significant advances in chemistry and the life sciences. They should represent a departure from current research directions rather than an extension or expansion of existing programs. Proposed research that cuts across traditional boundaries of scientific disciplines is encouraged. Proposals that open new avenues of research in chemistry and life sciences by fostering the invention of methods, instruments and materials will be given additional consideration. The BYI program funds promising young scientists early in their careers who have not yet received a major award from another organization. Proposals that already have substantial funding will not be considered for the BYI award (see eligibility for more information). Projects are normally funded for a period of four years. Grants are in the range of $600,000 over the term of the project, contingent upon demonstrated progress after the second year of the award.

This funding opportunity announcement (FOA) supports the development of PET radioligands that identify proteinopathies or pathological processes associated with the human biology of Alzheimer's disease related dementias (ADRDs). Activities supported under this FOA include, but are not limited to the in vitro screening of existing ligands against human ADRD brain tissue, medicinal chemistry support for development of new compounds and improvement of existing ligand specificity and selectivity, initial screening of ligands in appropriate animal models, and radioligand formulation and first-in-human testing. The Center without Walls should encompass research that will move promising ligands through in vitro and in vivo optimization to first-in-human studies. Applications must include an administrative core, a medicinal chemistry core, a clinical core, a scientific governance structure, and a minimum of two research projects with milestone plans that address workflows for screening of existing and newly derived ligands against human ADRD tissue and appropriate animal models. Synergy must be evident among Center research projects and cores, such that successful completion of the aims could not be accomplished without the Center structure. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2016 update to the National Plan to Address Alzheimer's Disease.

This funding opportunity announcement (FOA) invites applications for mentored career enhancement (K18) awards in research areas that are highly relevant to the NIH BRAIN Initiative. This career enhancement program will support development of research capability for the BRAIN Initiative, with specific emphasis on cross-training independent investigators in a substantively different area of neuroscience, neuroethics, or in a quantitative and physical discipline (e.g., physics, chemistry, engineering, computer science, mathematics); and vice versa, cross-training independent investigators trained in a quantitative or physical discipline proposing to gain in-depth training in a high-priority area of neuroscience. The research project conducted under this K18 should enhance the candidate's ability to significantly contribute to or lead projects that investigate questions central to the goals of the BRAIN Initiative. Eligible candidates are independent investigators at any faculty rank or level.

This funding opportunity announcement (FOA) invites applications for mentored career enhancement (K18) awards in research areas that are highly relevant to the NIH BRAIN Initiative. This career enhancement program will support development of research capability for the BRAIN Initiative, with specific emphasis on cross-training independent investigators in a substantively different area of neuroscience, neuroethics, or in a quantitative and physical discipline (e.g., physics, chemistry, engineering, computer science, mathematics); and vice versa, cross-training independent investigators trained in a quantitative or physical discipline proposing to gain in-depth training in a high-priority area of neuroscience. The research project conducted under this K18 should enhance the candidate's ability to significantly contribute to or lead projects that investigate questions central to the goals of the BRAIN Initiative. Eligible candidates are independent investigators at any faculty rank or level.

This funding opportunity announcement(FOA) supports the development of PET radioligands that identify proteinopathies or pathological processes associated with the human biology of Alzheimer's disease related dementias (ADRDs). Activities supported under this FOA include, but are not limited to the in vitro screening of existing ligands against human ADRD brain tissue, medicinal chemistry support for improvement of ligand specificity and selectivity, initial screening of ligands in appropriated animal models, and radioligand formulation and first-in-human testing. Applications must include an administrative core, a medicinal chemistry core, a clincial core, a scientific governance structure, and a minimum of two research projects with milestone plans that address workflows for screening of existing and newly derived ligands against human ADRD tissue and appropriate animal models. Synergy must be evident among Center research projects and cores, such that successful completion of the aims could not be accomplished without the Center structure. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2016 update to the National Plan to Address Alzheimer's Disease.

Reissue of PAR-18-541. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

Candidates must hold a Ph.D. (or equivalent) in chemistry, computational or evolutionary molecular biology, computer science, economics, mathematics, neuroscience, ocean sciences (including marine biology), physics, or a related field; Candidates must hold a tenure track (or equivalent) position at a college, university or other degree-granting institution in the United States or Canada;  Candidates must normally be no more than six years from completion of their most recent Ph.D. (or equivalent) as of the year of their nomination.  (That is, most recent Ph.D. must have been awarded on or after September 2007.)** While Fellows are expected to be at an early stage of their research careers, there should be strong evidence of independent research accomplishments. Candidates in all fields are normally below the rank of associate professor and do not hold tenure, but these are not strict requirements. The Alfred P. Sloan Foundation welcomes nominations of all candidates who meet the traditional high standards of this program, and strongly encourages the participation of women and members of underrepresented minority groups.

The Alzheimer's Drug Discovery Foundation has issued a Request for Proposals for its Preclinical Drug Discovery program. Through the program, grants of up to $600,000 over two years will be awarded to promising preclinical drug discovery programs relevant to Alzheimer's disease, related dementias, and cognitive aging. Preclinical research funding priorities include high throughput screening, medicinal chemistry hit-to-lead development and optimization, in vitro and in vivo efficacy studies, ADME, toxicology, pharma-cokinetics and pharma-co-dynamics, and in vivo proof-of-concept with lead compounds and biologics. Program areas of particular interest include new chemical compounds for Alzheimer's disease, preclinical proof-of-concept, and re-purposing. With regards to potential drug targets, ADDF is interested in novel targets that include but are not limited to neuro-inflammation, protein degradation/autophagy, growth factor signaling, synaptic function/morphology, calcium regulation, energy utilization/mitochondria function, insulin sensitivity, epigenetics, ApoE function and cholesterol metabolism, vascular injury and the blood-brain barrier interface, cognitive enhancers, myelin changes, ischemia and oxidative stress, and tau-related toxicities. To be eligible, applicants must be academic investigators seeking to create and support innovative translational programs in academic medical centers and universities; biotechnology companies with programs dedicated to Alzheimer's disease translational development; and new biotechnology company spinouts or existing biotechnology companies that demonstrate a clear need for nonprofit funding. Funding is provided through program-related investments (PRIs) that require a return on investment based on scientific and/or business milestones.

The HFSP supports novel, innovative and interdisciplinary basic research focused on the complex mechanisms of living organisms; topics range from molecular and cellular approaches to systems and cognitive neuroscience and the interactions between organisms. A clear emphasis is placed on novel collaborations that bring biologists together with scientists from fields such as physics, mathematics, chemistry, computer science and engineering to focus on problems at the frontier of the life sciences.

This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents. *Also listed under R21

The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, mechanisms of drug action, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies, or discovery activities such as high throughput screening and hit optimization.

Grants of up to $150,000 will be awarded for research on the pathologic mechanisms underlying FTD. Priority will be given to projects related to the development and testing of novel high-throughput screening assays; identification and in vitro testing of potentially disease modifying compounds or biologics, including medicinal chemistry refinement, ADME, toxicology, pharmacokinetics, and pharmacodynamics studies; testing of novel lead compounds, biologics, or repurposed drug candidates in a relevant animal model for preclinical proof of concept; and/or development and/or characterization of new model organisms or cellular models in support of drug-discovery efforts. Funding is provided through mission-related investments that require return on investment based on scientific and/or business milestones.

To foster innovative collaborative approaches to research projects that propose novel pairings of investigators from at least two broadly disparate disciplines. The proposal must focus on the collaborative relationship, such that the scientific objectives could not be achieved without the efforts of at least two co-principal investigators and their respective disciplines. The combination and integration of studies may be inclusive of basic, clinical, population, behavioral, and/or translational research. Projects must include at least one Co-PI from a field outside cardiovascular disease and stroke. This award is also intended to foster collaboration between established and early- or mid-career investigators. Applications by existing collaborators are permitted, provided that the proposal is for a new and novel idea or approach that has not been funded before. Multidisciplinary research broadly related to cardiovascular function, cardiovascular disease, and stroke, or to related clinical, basic science, bioengineering, biotechnology, or public health problems. Proposals are encouraged from all basic science disciplines as well as epidemiological, behavioral, community and clinical investigations that bear on cardiovascular and stroke problems. AHA awards are open to the array of academic and health professionals. This includes but is not limited to all academic disciplines (biology, chemistry, engineering, mathematics, technology, physics, etc.) and all health-related professions (physicians, nurses, advanced practice nurses, pharmacists, dentists, physical and occupational therapists, statisticians, nutritionists, behavioral scientists, health attorneys, engineers, etc.).

Within the framework of the For Women in Science partnership between the L'Oréal Foundation and UNESCO, we are launching the 2014 call for nominations for outstanding women scientist form all over the world. Five 100.000$ prizes will be awarded in march 2014 in Paris to five women scientists, one per region, for the contributions of their research, the strength of their commitments and their impact on society. An international Jury of eminent scientists presided in 2013 by the Nobel Prize winner, Ahmed Zewali, makes the final selection.

The New Scholars Program supports projects to help early- to mid-career women scientists balance family responsibilities with demanding academic careers. New Scholars seeks to actively address the attrition rate of talented women scientists caused by work-life balance issues.

The purpose of this Dear Colleague Letter is to advise you about funding opportunities at the National Science Foundation for the research community to propose research projects or workshops that will gather data on the implementation and impacts of recent science policy initiatives including, but not limited to those noted earlier.  Especially encouraged are proposals that will: Develop new, or improve existing, analytical frameworks for evaluating the impacts of federal science policy initiatives; Explore different agencies' approaches to the implementation of particular policies to examine how variations in approach affect the achievement of intended policy outcomes; Collect case-study or quantitative data that facilitate identification of best practices in science and innovation policy implementation.

The INSPIRE awards program was established to address some of the most complicated and pressing scientific problems that lie at the intersection of traditional disciplines.  It is intended to encourage investigators to submit bold, exceptional proposals that some may consider to be at a disadvantage in a standard NSF review process; it is not intended for proposals that are more appropriate for existing award mechanisms.